← back to search

Liang Xu

Yunnan Academy of Forestry · SG
Area of research
Molecular Biology · Cancer Research
Research interest
Research interests include MicroRNA in disease regulation, RNA Research and Splicing, Cancer-related molecular mechanisms research, and Ubiquitin and proteasome pathways.
h-index
40
citations
5,753
works
180
NIH funding
primary concept
Medicine
email

Recent publications

XPO1 inhibitor KPT-330 disrupts the core transcriptional regulatory circuitry of dedifferentiated liposarcoma by modulating the translation process.
2026cited by 0position: contributordoi
Redistribution of super-enhancers promotes malignancy in human hepatocellular carcinoma.
2026cited by 0position: contributordoi
A fibroblast-like endothelial cell state promotes atherosclerosis via C/EBPβ-activated TGF-β signaling.
2026cited by 0position: contributordoi
Exploiting targeted degradation of cyclins and cyclin-dependent kinases for cancer therapeutics: a review.
2025cited by 1position: contributordoi
The constitutive 20S proteasome is required for the maintenance and differentiation of spermatogonia in mice.
2025cited by 0position: contributordoi
Supplementary file from Targeting RNA Exonuclease XRN1 Potentiates Efficacy of Cancer Immunotherapy
2025cited by 0position: contributordoi
Targeting RNA Exonuclease XRN1 Potentiates Efficacy of Cancer Immunotherapy.
2023cited by 16position: contributordoi
Data from Targeting RNA Exonuclease XRN1 Potentiates Efficacy of Cancer Immunotherapy
2023cited by 0position: contributordoi
Supplementary file from Targeting RNA Exonuclease XRN1 Potentiates Efficacy of Cancer Immunotherapy
2023cited by 0position: contributordoi
Supplementary file from Targeting RNA Exonuclease XRN1 Potentiates Efficacy of Cancer Immunotherapy
2023cited by 0position: contributordoi
Data from Targeting RNA Exonuclease XRN1 Potentiates Efficacy of Cancer Immunotherapy
2023cited by 0position: contributordoi
The aberrant upregulation of exon 10-inclusive SREK1 through SRSF10 acts as an oncogenic driver in human hepatocellular carcinoma
Nature Communications 2022cited by 75position: middledoi
The aberrant upregulation of exon 10-inclusive SREK1 through SRSF10 acts as an oncogenic driver in human hepatocellular carcinoma.
2022cited by 36position: contributordoi
Topography of transcriptionally active chromatin in glioblastoma.
2021cited by 28position: contributordoi
PON2 subverts metabolic gatekeeper functions in B cells to promote leukemogenesis
Proceedings of the National Academy of Sciences 2021cited by 19position: middledoi
MNK1 and MNK2 enforce expression of E2F1, FOXM1, and WEE1 to drive soft tissue sarcoma.
2021cited by 16position: contributordoi
A prospective study on vulvovaginal candidiasis: multicentre molecular epidemiology of pathogenic yeasts in China
Journal of the European Academy of Dermatology and Venereology 2021cited by 14position: middledoi
TP63, SOX2, and KLF5 Establish a Core Regulatory Circuitry That Controls Epigenetic and Transcription Patterns in Esophageal Squamous Cell Carcinoma Cell Lines
Gastroenterology 2020cited by 183position: middledoi
Core transcriptional regulatory circuitries in cancer
Oncogene 2020cited by 91position: middledoi
Core transcriptional regulatory circuitries in cancer.
2020cited by 65position: contributordoi
Microarray Analysis of Gene Expression Provides New Insights Into Denervation-Induced Skeletal Muscle Atrophy
Frontiers in Physiology 2019cited by 110position: middledoi
Bromodomain and extraterminal proteins foster the core transcriptional regulatory programs and confer vulnerability in liposarcoma
Nature Communications 2019cited by 62position: middledoi
Bromodomain and extraterminal proteins foster the core transcriptional regulatory programs and confer vulnerability in liposarcoma.
2019cited by 46position: contributordoi
Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations.
2019cited by 33position: contributordoi
TP63, SOX2 and KLF5 Establish Core Regulatory Circuitry and Construct Cancer Specific Epigenome in Esophageal Squamous Cell Carcinoma
bioRxiv (Cold Spring Harbor Laboratory) 2019cited by 3position: middledoi
Co-activation of super-enhancer-driven CCAT1 by TP63 and SOX2 promotes squamous cancer progression
Nature Communications 2018cited by 238position: middledoi
Targetable BET proteins- and E2F1-dependent transcriptional program maintains the malignancy of glioblastoma
Proceedings of the National Academy of Sciences 2018cited by 121position: firstdoi
Silencing NKG2D ligand-targeting miRNAs enhances natural killer cell-mediated cytotoxicity in breast cancer
Cell Death and Disease 2017cited by 85position: middledoi
BCL6 promotes glioma and serves as a therapeutic target
Proceedings of the National Academy of Sciences 2017cited by 81position: firstdoi
ROCK‐dependent phosphorylation of NUP62 regulates p63 nuclear transport and squamous cell carcinoma proliferation
EMBO Reports 2017cited by 78position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

H. Phillip Koeffler · Duke-NUS Medical School22 papers (2013–2025)De‐Chen Lin · University of Southern California17 papers (2013–2025) · 16 papers (2019–2026)Ling‐Wen Ding · National University of Singapore9 papers (2013–2019)Ling-Wen Ding · Guizhou University8 papers (2019–2025)Anand Mayakonda · National University of Singapore8 papers (2016–2020)Masaharu Hazawa · Frontier Science Foundation8 papers (2014–2020)Yan‐Yi Jiang · Second Hospital of Anhui Medical University7 papers (2014–2020) · 7 papers (2019–2025) · 7 papers (2021–2025)Henry Yang · National University of Singapore7 papers (2013–2017)Lingzhi Wang · Jishou University6 papers (2023–2025)Zhentang Lao · National University Cancer Institute, Singapore6 papers (2023–2025)Xinyi Loh · Oklahoma State University6 papers (2023–2025)Vikas Madan · Experimental Drug Development Centre6 papers (2023–2025)Jonathan W. Said · University of California, Los Angeles6 papers (2023–2025)Henry Yang · National University Health System6 papers (2023–2025) · 6 papers (2023–2025)Boon Cher Goh · Center for Translational Molecular Medicine6 papers (2023–2025)Sudhakar Jha · National Cancer Centre Singapore6 papers (2023–2025)